Chemistree Acquires Ownership Stake in The Physician's Choice CBD LLC

Published: April 30, 2019

Chemistree Acquires Ownership Stake in The Physician's Choice CBD LLC

Chemistree Technology Inc. has entered into a funding agreement with The Physician’s Choice CBD LLC of Phoenix, Arizona. The Physician’s Choice CBD (“PCCBD”) is dedicated to research, development, and utilization of the highest quality of hemp-derived cannabidiol (CBD) combined with well-studied and effective supplements specific to help regulate and support various symptoms. The integration of extensive physician clinical experience combined with exhaustive expertise in the cannabis industry has led to the creation of The Physician’s Choice CBD.

Established in 2018, PCCBD has already developed a suite of nine full spectrum CBD from Hemp products ranging from pain/inflammation management to sleep and wellness supplements. In it’s first quarter of sales ended January 2019, the company booked approximately $150,000 in sales. The products are available for purchase at www.pccbd.com and distributed through healthcare providers across the U.S. The Physicians Choice CBD offers complete wholesale programs as well as a referral program compensating healthcare providers on purchases from codes provided to their patients.

With over 15 years in private practice, Dr. Julian Grove, M.D. and Dr. Peter Kubitz, D.O., have experienced first-hand the difficulties and complex dilemmas in treating patients suffering from chronic pain. From a medical management perspective, the treatment of pain is at a crossroads as for the last two decades, the intersection of various forms of pain medications and the prominent and real consequences of their use has created a globally recognized problem. The side effects, end-organ damage, and the potential for addiction and abuse are global concerns. As providers treating patients with complex pain daily, the doctors offer patients a myriad of different treatments including physical therapy, interventional therapies (nerve blocks, spinal cord stimulation), and complementary treatments (chiropractic, naturopathic medicine, massage, acupuncture, psychological support). Unfortunately, many times, this is not enough.

Dr. Grove stated, “Managing various pain syndromes with medications that do not exacerbate severe medical conditions and behavioral risk factors is an ongoing challenge for medical professionals. This has been a driving force in the development of a product line of cannabidiol products, aiding in the management of specific pain syndromes and improve a sense of well-being.”

Chemistree president Karl Kottmeier commented “This investment in The Physician’s Choice CBD is a great opportunity for Chemistree. Dr. Grove and Dr. Kubitz are board certified practicing physicians with training at Harvard and the Mayo Clinic, specializing in pain management. Their collective education and practical experience is industry-leading and their commitment to the health of their patients and to developing real solutions to pain management with cannabidiol-based supplements is truly inspiring. The investment we are making into PCCBD gives us exposure to an entirely new industry and we are excited to assist whereever we can to see PCCBD continue to grow its sales and product offerings into a multi-state success. I encourage everyone to visit www.pccbd.com to learn more about this great new company and their comprehensive and growing line of CBD supplements.”

Recent News

View All News Items

Latest Article

Artificial Intelligence, Learning and Explosive Growth in Cannabis

Artificial Intelligence, Learning and Explosive Growth in Cannabis

Organizations operating in the industry have a distinct need for clear communication across multiple departments and sophisticated ways of training new employees quickly to ensure compliance, efficiency and more. Companies looking to grow and capitalize need to be agile and have the ability to train employees on the latest information necessary for success.

Read Article